Blog | HemaCare

Prevent Recurring Tumors with Immunotherapy

May 14, 2018 10:13:00 AM / by Stacy Matthews Branch, DVM, PhD posted in new immunotherapy advances, cancer immunotherapy, Dendritic Cell Immunotherapy, Dendritic Cells, Immunotherapy, tumor cells, Tumors


Immunotherapy is becoming a promising treatment approach for cancer patients with recurring tumors, and more studies will help to further develop the treatment options.

Surgical resection is still the first-line treatment for solid tumors despite the rate of tumor recurrence with this approach. Surgery to remove tumors provokes wound healing processes that promote local immunosuppressive environments and metastasis. Surgical resection of tumors can also remove beneficial immune cells and factors that could promote targeting and killing of tumor cells. Radio- or chemotherapy as an adjunct to surgery has some limited effects on distant metastasis, but these treatments are associated with significant systemic adverse effects. 

Read More

Dendritic Cells Change Game for Immunotherapy for Cancer Patients

May 7, 2018 10:07:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Dendritic Cell Immunotherapy, dendritic cell vaccine, Dendritic Cells, Immunotherapy


Further development and wider use of dendritic cell-based anticancer vaccines has the potential to significantly increase cancer survival rates and improve the quality of life and function with fewer adverse effects.

Anticancer therapy using the patient’s own immune cells is an ever-growing area of cancer research that supports personalized medical efforts. This approach in immunotherapy provides specific results that can spare normal tissue and considerably decrease adverse side effects. The use of dendritic cells, powerful antigen-presenting cells of the immune system, is extensively studied. Positive gains have been realized in this arena and are changing the face of cancer therapy.

Read More

Cytokine-Induced Killer Cell/Dendritic Cell Immunotherapy Combined with Chemotherapy is More Effective than Chemotherapy Alone

May 31, 2017 1:00:17 AM / by Stacy Matthews Branch, DVM, PhD posted in bioreasearch, bioresearch products, cell products, Dendritic Cell Immunotherapy, Dendritic Cells, Immunotherapy


Colorectal cancer (CRC) is the fourth most common type of cancer in the U.S. , but screening and early diagnosis have helped to reduce the death rate from CRC in the U.S. However, developing and transitional countries experience increases in the incidence of CRC. The primary treatment approaches used (surgery, chemotherapy, radiotherapy) are associated with adverse events and poor survival rates.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts